Search

Your search keyword '"Usmani, S.Z."' showing total 11 results
Start Over Author "Usmani, S.Z." Publication Type Academic Journals
11 results on '"Usmani, S.Z."'

1. CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Moreau, P., Usmani, S.Z., van de Donk, N.W.C.J., Garfall, A.L., Delforge, M., Oriol, A., Nooka, A., Rosiñol, L., Bahlis, N., Rodríguez Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Chastain, K., Marshall, A., Slavcev, M., Londhe, A., and Krishnan, A.

Published
2023
Full Text
View/download PDF

3. P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Moreau, P., Usmani, S.Z., van de Donk, N.W.C.J., Garfall, A.L., Delforge, M., Oriol, A., Nooka, A., Rosiñol, L., Bahlis, N., Rodriguez Otero, P., Martin, T.G., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Chastain, K., Marshall, A., Slavcev, M., Londhe, A., and Krishnan, A.

Published
2023
Full Text
View/download PDF

5. UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Author

Berdeja, J.G., Madduri, D., Usmani, S.Z., Singh, I., Zudaire, E., Yeh, T.M., Allred, A.J., Olyslager, Y., Banerjee, A., Goldberg, J.D., Schecter, J., Geng, D., Wu, X., Carrasco-Alfonso, M.J., Rizvi, S., Fan, F., Jakubowiak, A., and Jagannath, S.

Published
2020
Full Text
View/download PDF

11. Insight into human protease activated receptor-1 as anticancer target by molecular modelling.

Author

Hidayat, A.N., Aki-Yalcin, E., Beksac, M., Tian, E., Usmani, S.Z., Ertan-Bolelli, T., and Yalcin, İ.

Subjects
CANCER treatment, ANTINEOPLASTIC agents, TARGETED drug delivery, PHENOTYPES, PROTEOLYTIC enzymes, CANCER cell proliferation, MOLECULAR models
Abstract

Protease-activated receptor 1 (PAR1) has been established as a promising target in many diseases, including various cancers. Strong evidence also suggests its role in metastasis. It is proved experimentally that PAR1 can induce numerous cell phenotypes, i.e. proliferation and differentiation. A strong link between PAR1 gene overexpression and high levels of ß-catenin was suggested by a study of the PAR1–Gα(13)–DVL axis in ß-catenin stabilization in cancers. An in vitro study was carried out to analyze PAR1 expression by flow cytometry on CD38+138+ plasma cells obtained from patients either at diagnosis (n: 46) (newly diagnosed multiple myeloma (NDMM)) or at relapse (n: 45) (relapsed/refractory multiple myeloma (RRMM)) and compared with the controls. Our previously synthesized benzoxazole (XT2B) and benzamide (XT5) derivatives were tested with in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, which revealed significant inhibitory activity on PAR1. We provide docking studies using Autodock Vina of these newly tested compounds to compare with the known PAR1 inhibitors in order to examine the binding mechanisms. In addition, the docking results are validated using HYDE binding assessment and a neural network (NN) scoring function. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results